原发性膜性肾病诊断及治疗新进展  

Progress of primary membranous nephropathy in diagnosis and treatment

作　　者：伍敏[1] 魏青[1] 刘必成[1] WU Min;WEI Qing;LIU Bi-cheng(Department of Nephrology,Southeast University afiliated Zhongda Hospital,Institute of Nephrology,Southeast Universty,Nanjing 210009,China)

机构地区：[1]东南大学附属中大医院肾脏科东南大学肾脏病研究所,江苏南京210009

出　　处：《中国实用内科杂志》2023年第3期183-187,共5页Chinese Journal of Practical Internal Medicine

基　　金：江苏省自然科学基金(BK20191263)。

摘　　要：原发性膜性肾病(pMN)是一种自身免疫性疾病,发病主要与磷脂酶A2受体(PLA2R)等多种足细胞抗原诱发机体免疫活化有关。尽管肾活检病理仍是pMN确诊的关键手段,越来越多研究提示,血清PLA2R抗体可作为生物标志物,在pMN诊断和临床疗效预测中发挥重要作用。pMN常见临床表现为肾病综合征,免疫抑制剂是常用治疗方法,近年来多种生物制剂应用于pMN治疗,使部分难治性肾病综合征获得缓解。文章对pMN诊治新进展进行概述。Primary membranous nephropathy(pMN)is an auto-immune disease,which is mainly related to the immune activation induced by various podocyte antigens such as phospholipase A2 receptor(PLA2R).Although renal biopsy is still the key method for the diagnosis of p MN,emerging evidence has suggested that serum PLA2R antibody can be used as a biomarker for the diagnosis of p MN and prediction of clinical efficacy.The common clinical manifestation of pMN is nephrotic syndrome and immunosuppressive treatment should be considered as a common therapeutic strategy.In recent years,a variety of biological agents have been used in the treatment of pMN,which has improved some refractory nephrotic syndrome.This article briefly reviews the latest progress in the diagnosis and treatment of pMN.

关 键 词：原发性膜性肾病 磷脂酶A2受体 免疫抑制剂 

分 类 号：R692[医药卫生—泌尿科学]